Scolaris Content Display Scolaris Content Display

Table 1. Radiotherapy regimens and biological effective doses (BED)

RT REGIMEN

STUDY

BED(10): Gy

BED(25): Gy

BED(1.7): Gy

60Gy/39F/6W

Nestle 2000

72

65

131

50Gy/25F/5W

Reinfuss 1999; Sundstrom 2004

60

54

109

45Gy/15/3.5W (4 days per week)

Abratt 1995

59

50

109

45Gy/18F/3.4W

Teo 1988

56

50

111

40GY/10F/4W(split)

Reinfuss 1999; Simpson 1985

56

46

134

42Gy/15F/3W

Sundstrom 2004

54

47

111

39Gy/13F/2.4W

MRC 1996

51

44

108

40Gy/20F/4W

Simpson 1985

48

43

87

36Gy/12F/2.3W

MRC1996

47

40

100

35Gy/10F/2.2W (4 days per week)

Abratt 1995

47

40

107

32Gy/16F/10d (twice daily)

Nestle 2000

38

35

70

31.2Gy/4F/4W (weekly)

Teo 1988

55

41

174

30Gy/10F/2W

MRC 1991, Simpson 1985, Kramer 2005, Erridge 2005

39

34

83

27Gy/6F/2W (3 days per week)

MRC 1991

39

32

98

22.5Gy/5F/5d

Rees 1997

33

27

82

20Gy/5F/5d

Senkus‐Konefka 2005, Bezjak 2002

28

23

67

17Gy/2F/8d (weekly)

MRC 1991, MRC 1992, MRC 1996, Rees 1997, Sundstrom 2004

31

23

102

16Gy/2F/8d (weekly)

Senkus‐Konefka 2005, Kramer 2005

29

21

91

10Gy/1F/1d

MRC 1992, Bezjak 2002, Erridge 2005

20

14

69

BED(y): biologically effective dose (Gy), calculated by the formula: BED(y) = n x d (1+ d/ (alpha/beta)), where n=number of fractions, d= size of each fraction(Gy), and alpha/beta is constant, of value y, for a given tissue type (Fowler 1989, Joiner 1997)

Figuras y tablas -
Table 1. Radiotherapy regimens and biological effective doses (BED)
Table 2. Survival data (*estimated from published data)

STUDY

RT REGIMEN

Performance Status

Median survival

1‐year survival

2‐year survival

Abratt 1995

45Gy/15F

WHO 0‐2

8.5 months

37%

N/A

Abratt 1995

35Gy/10F

WHO 0‐2

8.5 months

40%

N/A

MRC 1991

30Gy/10F

Any

5.9 months

23%

5%

MRC 1991

17Gy/2F

Any

6.0 months

20%

5%

MRC 1992

17Gy/2F

WHO 2‐4

3.3 months

14%

2%

MRC 1992

10Gy/1F

WHO 2‐4

4.0 months

9%

3%

MRC 1996

17Gy/2F

WHO 0‐2

7 months

31%

12%

MRC 1996

36‐39Gy/12‐13F

WHO 0‐2

9 months

36%

9%

Nestle 2000

32Gy/16F

KPS >50

8.4 months

38%

9%

Nestle 2000

60Gy/30F

KPS>50

8.3 months

36%

9%

Rees 1997

17Gy/2F

Any

6 months*

18%*

5%*

Rees 1997

22.5Gy/5F

Any

6 months*

22%*

12%*

Reinfuss 1999

40Gy/10F (split)

KPS >50

8.3 months

28%

6%

Reinfuss 1999

50Gy/25F

KPS >50

12 months

48%

18%

Simpson 1985

30Gy/10F

KPS >60

6.4 months

22%*

8%*

Simpson 1985

40Gy/20F

KPS >60

6.9 months

30%*

8%*

Simpson 1985

40Gy/20F (split)

KPS >60

6.2 months

30%*

8%*

Sundstrom 2004

17Gy/2F

Any

8.2 months

29%

8%

Sundstrom 2004

42Gy/15F

Any

7 months

29%

13%

Sundstrom 2004

50Gy/25F

Any

6.8 months

31%

10%

Teo 1988

31Gy/4F

Any

5 months

18%*

5%

Teo 1988

45Gy/18F

Any

5 months

22%*

5%

Senkus‐Konefka

20Gy/5F

WHO 1‐4

5.3 months

11%

N/A

Senkus‐Konefka

16Gy/2F

WHO 1‐4

8 months

27%

N/A

Kramer

16Gy/2F

WHO 3‐4, or stage 4 WHO 0‐2

N/A

10.9%

N/A

Kramer

30Gy/10F

WHO 3‐4, or stage 4 WHO 0‐2

N/A

19.6%

N/A

Bezjak

10Gy/1F

WHO 0‐3

4.2 months

15%*

N/A

Bezjak

20Gy/5F

WHO 0‐3

6 months

26%*

N/A

Erridge

30Gy/10F

WHO 0‐3

22.7 weeks

28%

8%

Erridge

10Gy/1F

WHO 0‐3

28.3 weeks

19%

4%

Figuras y tablas -
Table 2. Survival data (*estimated from published data)